PremiumThe FlyOptinose downgraded to Hold from Buy at Lake Street Paratek Pharmaceuticals to acquire Optinose in $330M transaction PremiumThe FlyOptinose price target adjusted for stock split at H.C. Wainwright OptiNose trading halted, volatility trading pause PremiumCompany AnnouncementsOptinose Shows Prescription Growth Amid Revenue Challenges Optinose reports Q3 EPS 0c, consensus (5c) Optinose cuts FY24 XHANCE revenue view to $75M-$79M from $85M-$90M 
